Abstract
Tardive dyskinesia (TD) is a debilitating side-effect of antipsychotic treatment associated with reduced compliance and quality of life. TD prevalence is difficult to estimate accurately and is influenced by the increased use of antipsychotic drugs and the aging of the population. We assessed the prevalence, severity and characteristics of TD among schizophrenia patients at a university-affiliated psychiatric center in Israel. One hundred and twenty eight patients with schizophrenia were recruited and underwent demographic and clinical assessments. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Forty five subjects met probable TD criteria (prevalence: 35.2%; 95% CI 26.9% -44.1 %.). Subjects with TD were older and had a longer duration of treatment with antipsychotic medications. Diabetes mellitus, hypertension, head injuries and more severe psychiatric symptomatology did not predict TD. Patients in the TD-group had higher rates of extrapyramidal symptoms (EPS) and were more likely to receive an anticholinergic agent. The type of antipsychotic medication was not found to be associated with TD occurrence. Our findings confirm the established relationships between presence of TD and age, duration of antipsychotics treatment, anticholinergic treatment and the presence of EPS. Furthermore, our data support recent findings indicating that TD is still a prevalent disorder representing an unresolved public health issue.
Keywords: Aging, anticholinergic agents, atypical and typical antipsychotics, extrapyramidal side-effects, schizophrenia, Tardive dyskinesia.
Current Psychopharmacology
Title:Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Volume: 3
Author(s): Rony Sabbag, Bitya Fridman and Uriel Heresco-Levy
Affiliation:
Keywords: Aging, anticholinergic agents, atypical and typical antipsychotics, extrapyramidal side-effects, schizophrenia, Tardive dyskinesia.
Abstract: Tardive dyskinesia (TD) is a debilitating side-effect of antipsychotic treatment associated with reduced compliance and quality of life. TD prevalence is difficult to estimate accurately and is influenced by the increased use of antipsychotic drugs and the aging of the population. We assessed the prevalence, severity and characteristics of TD among schizophrenia patients at a university-affiliated psychiatric center in Israel. One hundred and twenty eight patients with schizophrenia were recruited and underwent demographic and clinical assessments. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Forty five subjects met probable TD criteria (prevalence: 35.2%; 95% CI 26.9% -44.1 %.). Subjects with TD were older and had a longer duration of treatment with antipsychotic medications. Diabetes mellitus, hypertension, head injuries and more severe psychiatric symptomatology did not predict TD. Patients in the TD-group had higher rates of extrapyramidal symptoms (EPS) and were more likely to receive an anticholinergic agent. The type of antipsychotic medication was not found to be associated with TD occurrence. Our findings confirm the established relationships between presence of TD and age, duration of antipsychotics treatment, anticholinergic treatment and the presence of EPS. Furthermore, our data support recent findings indicating that TD is still a prevalent disorder representing an unresolved public health issue.
Export Options
About this article
Cite this article as:
Sabbag Rony, Fridman Bitya and Heresco-Levy Uriel, Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center, Current Psychopharmacology 2014; 3 (1) . https://dx.doi.org/10.2174/2211556003666140319231741
DOI https://dx.doi.org/10.2174/2211556003666140319231741 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Brain-derived Neurotrophic Factor Genetic Variants are Associated with Major Depression Susceptibility and Serotonin Reuptake Inhibitor Antidepressant Treatment Response in Taiwanese
Current Pharmacogenomics and Personalized Medicine Pharmacological Studies of Smooth Pursuit and Antisaccade Eye Movements in Schizophrenia: Current Status and Directions for Future Research
Current Neuropharmacology Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry In Vitro Metabolism Studies of New Adenosine A Receptor Antagonists
Drug Metabolism Letters Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism
Current Pharmaceutical Design Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Olfactory Loss and Dysfunction in Ciliopathies: Molecular Mechanisms and Potential Therapies
Current Medicinal Chemistry Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology Restoration of the Striatal Dopamine Synthesis for Parkinsons Disease:Viral Vector-Mediated Enzyme Replacement Strategy
Current Gene Therapy Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design